newsfilter
← Latest News
ACCESS Newswire·

NanoViricides Awaits Approval from DR Congo Regulatory Agency for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola, Financing Completed to Support the Trial

SHELTON, CT / ACCESS Newswire / July 28, 2026 / NanoViricides, Inc. , a clinical stage leader developing antiviral drugs that viruses cannot escape, announces that it is eagerly